EuroPCR 2025 | Individual Patient Data Meta-analysis of PROTECTED TAVR and BHF PROTECT-TAVI

Stroke remains a significant complication associated with the various transcatheter aortic valve implantation (TAVI) devices currently in use. The Sentinel cerebral embolic protection (CEP) device could capture embolic debris during TAVI procedures; however, randomized trials have so far failed to show a significant reduction in stroke incidence.

Two major studies were conducted: PROTECTED TAVR (3,000 patients, primarily from the U.S.) and BHF PROTECT-TAVI (7,635 patients from the U.K.), both evaluating stroke occurrence within 72 hours post-TAVI or at hospital discharge. In both trials, a non-significant reduction in neurovascular events was observed (-0.6%, p=0.30 and -0.02%, p=0.94, respectively).

Based on these data, researchers carried out a meta-analysis of individual patient data. A primary analysis assessed stroke incidence (within 72 hours or at discharge) between patients who received CEP and those who did not. A per-protocol analysis was also conducted, including only patients with both CEP filters correctly deployed.

Upon primary analysis, stroke incidence did not show significant differences. However, upon per-protocol analysis, the CEP group showed a lower stroke rate (2.3% vs. 1.7%; P=0.023), though not sustained after adjusting for confounding factors.

Read also: EuroPCR 2025 | Angiography- vs. Physiology-Guided PCI in TAVI Candidates (FAITAVI).

Regarding disabling stroke, the subgroup with proper positioning of both filters showed significantly lower incidence (1.3% vs. 0.8%; P=0.007) at per-protocol analysis.

The authors concluded that there is insufficient evidence to support the routine use of CEP to reduce stroke incidence. They emphasized the need to further identify high-risk subgroups that may benefit from this strategy.

Presented by R. Kharbanda during the Major Late Breaking Trials session, EuroPCR 2025, May 21, Paris, France.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...

Cardiac Remodeling After Percutaneous ASD Closure: Should It Be Immediate or Progressive?

Atrial septal defect (ASD) is a common congenital heart disease that generates a left-to-right shunt, leading to right-side chamber overload and a risk of...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...